Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Theramed Healthcare SRL (Romania) | UNKNOWN |
| Centre Hospitalier Universitaire de Toulouse, FRANCE | UNKNOWN |
| Charite-Universitaetsmedizin Berlin (Germany) | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The ClimAIr project will expand the evidence-based understanding of climate change, air pollution, and non-communicable respiratory diseases by using Artificial Intelligence (AI) tools. It will gather data on greenhouse gases levels and disaster risks, information on serious air pollutants and respiratory diseases' prevalence. The AI powered tools will be employed to generate better intervention methods and improve public health outcomes.
Federated Learning (FL) will be used to develop AI models to protect patients' privacy. By raising public awareness and delivering the ClimAIr tool - specifically designed to health workers, urban planners and policy makers - the project aims to influence policy decisions, promote healthier environments, and reduce respiratory diseases in Europe, which will be tested and validated the ClimAIr tool in specific municipalities that are part of the project. ClimAIr draws on a consortium of 21 partners from 15 European countries, including carefully selected health centres across Europe - in Spain, Luxembourg, Ukraine, Italy, France, Germany, Greece, Romania and Poland - focused on respiratory diseases, which will provide disease data and explore metabolic routes of the studied contaminants/diseases. ClimAIr is composed of an interdisciplinary team formed by research centres, ethical AI and modelling experts, SSH specialists, municipal governance, and a Communication & Dissemination (C&D) expert team dedicated to achieving and spread the results of the project.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| P01 - General Exposure Cohort | >200 AR patients per environmental condition. Includes patients exposed to various air pollutants, aiming to detect deleterious clinical effects. | ||
| P02 - Omics Synergistic Subgroup | Subgroup of 20 patients per environmental condition from P01. Selected based on exposure to multiple pollutants with observed synergistic effects on omics parameters. | ||
| S01 - Allergen-Specific Immune Response Subgroup | Subgroup of 25 patients per pollution condition from P01. Selected for in vitro assays to evaluate proliferation of peripheral allergen-specific lymphocytes in response to polluted pollen exposure. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Mean Symptom Score of Allergic Rhinitis Patients by Environmental Exposure | Mean allergic rhinitis symptom scores retrieved from electronic health records (EHR), stratified by environmental exposure levels (pollutants and climate factors), using the Observational Medical Outcomes Partnership (OMOP) common data model. | Retrospective data collected over a 3-year period prior to study enrollment. |
| Proteomic Biomarker Levels (NPX) by Environmental Exposure | Proteomic profiles measured using Olink® assays in serum and nasal lavage of allergic rhinitis patients, stratified by environmental exposure. | Samples collected prospectively between months 10 and 15 (October-March, out-of-pollen season). |
| Measure | Description | Time Frame |
|---|---|---|
| SO1: Effect of air pollution on adaptive immune responses to allergenic pollen | Evaluation of the immune response of peripheral blood mononuclear cells (PBMCs) from allergic rhinitis patients exposed to different environmental conditions, after in vitro stimulation with pollen samples previously exposed to varying pollution levels. The response will be characterized by proliferation of allergen-specific lymphocyte subsets and cytokine production. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Lack of reliable information in e-health records, allergen immunotherapy (any allergen) during the previous 5 years, systemic immunosuppressants or biologicals in the previous six months, chronic rhinosinusitis, and severe systemic conditions.
Not provided
Not provided
Not provided
Pacients with 3-year history of chronic rhinitis symptoms during the corresponding pollen seasonp ositive SPT and serum allergen-specific IgE >0.35 kUA/L.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ibon Eguiluz Gracia, MD, PhD | Contact | +34 951 291 073 | iboneguiluz@gmail.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D065631 | Rhinitis, Allergic |
| D001249 | Asthma |
| ID | Term |
|---|---|
| D012220 | Rhinitis |
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
| D012130 | Respiratory Hypersensitivity |
Not provided
Not provided
| Aristotelio Panepistimio Thessalonikis (Greece) |
| UNKNOWN |
| Uniwersytet Medyczny w Lodzi (Poland) | UNKNOWN |
| Universita degli Studi di Milano (Italy) | UNKNOWN |
| Bukovinian State Medical University (Ukraine) | UNKNOWN |
| Luxembourg Institute of Health | OTHER_GOV |
| Andaluz Health Service | OTHER_GOV |
Not provided
Not provided
Not provided
Peripheral blood : for serum ,DNA isolation and cellular assays. Nasal lavage: Bilateral lavage using isotonic saline by Naclerio method. Skin tape strips: 16 consecutive D-Squame tape strips applied to forearm for skin tissue sampling.
Analyses performed on samples include:
Proteomics (Olink®) on serum and nasal lavage supernatant Targeted metabolomics (LC-MS and GC-MS) on serum and nasal lavage DNA methylation profiling (Illumina EPIC array) from PBMC DNA Flow cytometry of PBMC cultured with pollen to assess lymphocyte proliferation and antibody production Multiplex ELISA for cytokine quantification in PBMC culture supernatants Microbiota analysis (16S, 18S, ITS2 sequencing) from nasal lavage pellets and skin tape strips
| Sample collection and analysis performed prospectively between months 10 and 24. |
| SO1: Proliferative responses of allergen-specific lymphocytes to pollen exposed to pollution | Measurement of lymphocyte proliferation using CFSE-labeled PBMCs incubated with pollen (Olea europaea, Phleum pratense, Betula pendula) grown under different pollution conditions. | Assays conducted on samples collected between months 10 and 24. |
| SO1: Cytokine release from allergen-specific lymphocytes in response to polluted pollen | Quantification of cytokines released in the supernatants of PBMC cultures stimulated with pollen under different pollution conditions. A multiplex ELISA panel will be used to measure Th1, Th2, Th9, and regulatory cytokine | Analysis performed between months 10 and 24, post-sample collection. |
| D010038 |
| Otorhinolaryngologic Diseases |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D001982 | Bronchial Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |